Miyake Makito, Nishimura Nobutaka, Nakai Yasushi, Fujii Tomomi, Owari Takuya, Hori Shunta, Morizawa Yosuke, Gotoh Daisuke, Anai Satoshi, Torimoto Kazumasa, Tanaka Nobumichi, Hirao Yoshihiko, Fujimoto Kiyohide
Department of Urology, Nara Medical University, Kashihara, Nara 634-8522, Japan.
Department of Diagnostic Pathology, Nara Medical University, Kashihara, Nara 634-8522, Japan.
Diagnostics (Basel). 2021 Jan 28;11(2):185. doi: 10.3390/diagnostics11020185.
Clinical evidence regarding risk reduction of repeated bladder recurrence after initial photodynamic diagnosis (PDD)-assisted transurethral resection of bladder tumor (TURBT) is still limited in patients with non-muscle-invasive bladder cancer (NMIBC). We analyzed patients with primary NMIBC undergoing TURBT without any adjuvant treatment to compare the risk of cumulative recurrence between the conventional white-light (WL)-TURBT and PDD-TURBT. Out of 430 patients diagnosed with primary NMIBC from 2010 to 2019, 40 undergoing WL-TURBT and 60 undergoing PDD-TURBT were eligible. Multivariate Cox regression analysis for time to the first recurrence demonstrated that PDD assistance was an independent prognostic factor with better outcome ( = 0.038, hazard ratio = 0.39, and 95% confidence interval 0.16-0.95). While no patient experienced more than one recurrence within 1000 postoperative days in the PDD-TURBT group, five out of 40 patients treated by WL-TURBT experienced repeated recurrence. The comparison of cumulative incidence per 10,000 person-days between the two groups revealed that PDD assistance decreased by 6.6 recurrences per 10,000 person-days (exact = 0.011; incidence rate ratio 0.37, Clopper-Pearson confidence interval 0.15-0.82). This is the first study addressing PDD assistance-induced risk reduction of repeated bladder recurrence using the person-time method. Our findings could support clinical decision making, especially on adjuvant therapy after TURBT.
对于非肌层浸润性膀胱癌(NMIBC)患者,关于初次光动力诊断(PDD)辅助经尿道膀胱肿瘤切除术(TURBT)后降低膀胱复发风险的临床证据仍然有限。我们分析了接受TURBT且未进行任何辅助治疗的原发性NMIBC患者,以比较传统白光(WL)-TURBT和PDD-TURBT之间的累积复发风险。在2010年至2019年诊断为原发性NMIBC的430例患者中,40例接受WL-TURBT,60例接受PDD-TURBT符合条件。对首次复发时间的多因素Cox回归分析表明,PDD辅助是一个独立的预后因素,预后更好(P = 0.038,风险比 = 0.39,95%置信区间0.16 - 0.95)。在PDD-TURBT组中,没有患者在术后1000天内经历超过一次复发,而在40例接受WL-TURBT治疗的患者中,有5例经历了反复复发。两组每10000人日累积发病率的比较显示,PDD辅助使每10000人日复发率降低6.6次(确切P = 0.011;发病率比0.37,Clopper-Pearson置信区间0.15 - 0.82)。这是第一项使用人时法探讨PDD辅助降低膀胱反复复发风险的研究。我们的研究结果可为临床决策提供支持,尤其是在TURBT后的辅助治疗方面。